Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.

Prorok PC, Wright P, Riley TR, Kramer BS, Berg CD, Gohagan JK.

Rev Recent Clin Trials. 2018 Apr 9. doi: 10.2174/1574887113666180409153059. [Epub ahead of print]

PMID:
29629665
2.

Validation: a critical step in bringing biomarkers to clinical fruition.

Srivastava S, Kramer BS.

Ann Epidemiol. 2018 Feb;28(2):135-138. doi: 10.1016/j.annepidem.2017.10.013. Epub 2017 Nov 9.

PMID:
29157735
3.

Editorial: Challenges in Quantifying Overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx064. No abstract available.

PMID:
29117354
4.

Incidental renal tumours on low-dose CT lung cancer screening exams.

Pinsky PF, Dunn B, Gierada D, Nath PH, Munden R, Berland L, Kramer BS.

J Med Screen. 2017 Jun;24(2):104-109. doi: 10.1177/0969141316657115. Epub 2016 Oct 9.

PMID:
28482765
5.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

Pinsky PF, Prorok PC, Kramer BS.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281. No abstract available.

PMID:
28355509
6.

Cancer Prevention: Lessons Learned and Future Directions.

Dunn BK, Kramer BS.

Trends Cancer. 2016 Dec;2(12):713-722. doi: 10.1016/j.trecan.2016.11.003. Review.

7.

Breast-Cancer Tumor Size and Screening Effectiveness.

Welch HG, Prorok PC, Kramer BS.

N Engl J Med. 2017 Jan 5;376(1):94-5. doi: 10.1056/NEJMc1614282. No abstract available.

8.

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman SM.

Cancer Prev Res (Phila). 2017 Feb;10(2):99-107. doi: 10.1158/1940-6207.CAPR-16-0230. Epub 2016 Dec 13. Review.

9.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

10.

The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications.

Doroudi M, Kramer BS, Pinsky PF.

J Med Screen. 2017 Dec;24(4):220-222. doi: 10.1177/0969141316680381. Epub 2016 Nov 30.

PMID:
27903809
11.

Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC.

Gynecol Oncol. 2016 Nov;143(2):270-275. doi: 10.1016/j.ygyno.2016.08.334. Epub 2016 Sep 9.

12.

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.

Welch HG, Prorok PC, O'Malley AJ, Kramer BS.

N Engl J Med. 2016 Oct 13;375(15):1438-1447.

13.

Population-based screening for cancer: hope and hype.

Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ.

Nat Rev Clin Oncol. 2016 Sep;13(9):550-65. doi: 10.1038/nrclinonc.2016.50. Epub 2016 Apr 13. Review.

PMID:
27071351
14.

Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.

Patz EF Jr, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR.

Lancet Oncol. 2016 May;17(5):590-9. doi: 10.1016/S1470-2045(15)00621-X. Epub 2016 Mar 18.

15.

Reply to J. Cabezas et al.

Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS.

J Clin Oncol. 2016 Jan 20;34(3):290-1. doi: 10.1200/JCO.2015.64.3064. Epub 2015 Dec 7. No abstract available.

PMID:
26644541
16.

Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.

Srivastava S, Reid BJ, Ghosh S, Kramer BS.

J Cell Physiol. 2016 Sep;231(9):1870-5. doi: 10.1002/jcp.25227. Epub 2016 Apr 29. Review.

17.

Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

Pinsky PF, Kramer BS.

J Natl Cancer Inst. 2015 Oct 19;107(11). pii: djv226. doi: 10.1093/jnci/djv226. Print 2015 Nov.

18.

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK, Steele VE, Fagerstrom RM, Topp CF, Ransohoff D, Cunningham C, Lubet R, Ford LG, Kramer BS.

J Natl Cancer Inst. 2015 Sep 28;107(12):djv259. doi: 10.1093/jnci/djv259. Print 2015 Dec.

19.

Study designs for determining and comparing sensitivities of disease screening tests.

Prorok PC, Kramer BS, Miller AB.

J Med Screen. 2015 Dec;22(4):213-20. doi: 10.1177/0969141315600003. Epub 2015 Sep 22.

PMID:
26396138
20.

Latent class instrumental variables: a clinical and biostatistical perspective.

Baker SG, Kramer BS, Lindeman KS.

Stat Med. 2016 Jan 15;35(1):147-60. doi: 10.1002/sim.6612. Epub 2015 Aug 4.

21.

Comprehensive Quality Management (CQM) in the PLCO Trial.

Gohagan JK, O'Brien B, Hasson MA, Umbel KD, Bridgeman B, Kramer BS, Reding D, Gren L, Wright P, Riley T, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):223-32.

PMID:
26238118
22.

The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.

Gohagan JK, Prorok PC, Greenwald P, Kramer BS.

Rev Recent Clin Trials. 2015;10(3):173-80. Review.

PMID:
26238115
23.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology.

Kent EE, Mitchell SA, Castro KM, DeWalt DA, Kaluzny AD, Hautala JA, Grad O, Ballard RM, McCaskill-Stevens WJ, Kramer BS, Clauser SB.

J Clin Oncol. 2015 Aug 20;33(24):2705-11. doi: 10.1200/JCO.2014.60.6210. Epub 2015 Jul 20.

24.

Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.

Baker SG, Kramer BS.

J Clin Oncol. 2015 Aug 10;33(23):2578-80. doi: 10.1200/JCO.2014.58.0092. Epub 2015 Jun 29. No abstract available.

25.

Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.

Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS.

J Clin Oncol. 2015 Jul 1;33(19):2212-20. doi: 10.1200/JCO.2015.61.3745. Epub 2015 May 11.

26.

Lung cancer risk by years since quitting in 30+ pack year smokers.

Pinsky PF, Zhu CS, Kramer BS.

J Med Screen. 2015 Sep;22(3):151-7. doi: 10.1177/0969141315579119. Epub 2015 Apr 29.

PMID:
25926339
27.

Projecting the benefits and harms of mammography using statistical models: proof or proofiness?

Kramer BS, Elmore JG.

J Natl Cancer Inst. 2015 Apr 29;107(7). pii: djv145. doi: 10.1093/jnci/djv145. Print 2015 Jul. No abstract available.

PMID:
25925581
28.

Colorectal cancer prevention and fishful thinking.

Umar A, Richmond E, Kramer BS.

J Natl Cancer Inst. 2015 Mar 25;107(4). pii: djv052. doi: 10.1093/jnci/djv052. Print 2015 Apr. No abstract available.

PMID:
25810493
29.

JNCI and cancer prevention.

Dunn BK, Ghosh S, Kramer BS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv021. doi: 10.1093/jnci/djv021. Print 2015 Mar.

30.

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF.

J Natl Cancer Inst. 2015 Feb 16;107(4). pii: djv012. doi: 10.1093/jnci/djv012. Print 2015 Apr.

31.

Conceptualizing overdiagnosis in cancer screening.

Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv014. doi: 10.1093/jnci/djv014. Print 2015 Apr.

32.

Multilevel modeling and value of information in clinical trial decision support.

Cui Y, Murphy B, Gentilcore A, Sharma Y, Minasian LM, Kramer BS, Coates PM, Gohagan JK, Klenk J, Tidor B.

BMC Syst Biol. 2014 Dec 24;8:6. doi: 10.1186/s12918-014-0140-0.

33.

Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Baker SG, Kramer BS.

Clin Trials. 2015 Aug;12(4):299-308. doi: 10.1177/1740774514557725. Epub 2014 Nov 10.

34.

Lead time and overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2014 Oct 31;106(12). pii: dju346. doi: 10.1093/jnci/dju346. Print 2014 Dec. No abstract available. Erratum in: J Natl Cancer Inst. J Natl Cancer Inst. 2015 Mar;107(3):doi/10.1093/jnci/djv019.

PMID:
25362702
35.

National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population.

Pinsky PF, Gierada DS, Hocking W, Patz EF Jr, Kramer BS.

Ann Intern Med. 2014 Nov 4;161(9):627-33. doi: 10.7326/M14-1484.

36.

Estimating overdiagnosis in lung cancer screening--reply.

Patz EF Jr, Pinsky P, Kramer BS.

JAMA Intern Med. 2014 Jul;174(7):1198-9. doi: 10.1001/jamainternmed.2014.1525. No abstract available.

PMID:
25003885
37.

Breast cancer screening: toward informed decisions.

Elmore JG, Kramer BS.

JAMA. 2014 Apr 2;311(13):1298-9. doi: 10.1001/jama.2014.2494. No abstract available. Erratum in: JAMA. 2014 Jul 9;312(2):192.

PMID:
24691605
38.

Future directions for postdoctoral training in cancer prevention: insights from a panel of experts.

Nelson DE, Faupel-Badger J, Phillips S, Belcher B, Chang S, Abrams DB, Kramer BS, White MC, O'Malley M, Varanasi AP, Fabian CJ, Wiest JS, Colditz GA, Hall K, Shields PG, Weitzel JN.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):679-83. doi: 10.1158/1055-9965.EPI-13-1209. Epub 2014 Mar 6.

39.

The randomized registry trial.

Baker SG, Kramer BS, Lindeman KS.

N Engl J Med. 2014 Feb 13;370(7):681-2. doi: 10.1056/NEJMc1315677. No abstract available.

40.

Overdiagnosis in low-dose computed tomography screening for lung cancer.

Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammem├Ągi MC, Chiles C, Black WC, Aberle DR; NLST Overdiagnosis Manuscript Writing Team.

JAMA Intern Med. 2014 Feb 1;174(2):269-74. doi: 10.1001/jamainternmed.2013.12738. Erratum in: JAMA Intern Med. 2014 May;174(5):828.

41.

The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.

Zhu CS, Pinsky PF, Kramer BS, Prorok PC, Purdue MP, Berg CD, Gohagan JK.

J Natl Cancer Inst. 2013 Nov 20;105(22):1684-93. doi: 10.1093/jnci/djt281. Epub 2013 Oct 10. Review.

42.

The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology.

Pinsky PF, Church TR, Izmirlian G, Kramer BS.

Cancer. 2013 Nov 15;119(22):3976-83. doi: 10.1002/cncr.28326. Epub 2013 Aug 26.

43.

The word "cancer": how language can corrupt thought.

Dunn BK, Srivastava S, Kramer BS.

BMJ. 2013 Sep 10;347:f5328. doi: 10.1136/bmj.f5328. No abstract available.

PMID:
24022035
44.

The risky reliance on small surrogate endpoint studies when planning a large prevention trial.

Baker SG, Kramer BS.

J R Stat Soc Ser A Stat Soc. 2013 Feb 1;176(2):603-608. Epub 2012 Jun 28.

45.

Transforming epidemiology for 21st century medicine and public health.

Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):508-16. doi: 10.1158/1055-9965.EPI-13-0146. Epub 2013 Mar 5.

46.

Surrogate endpoint analysis: an exercise in extrapolation.

Baker SG, Kramer BS.

J Natl Cancer Inst. 2013 Mar 6;105(5):316-20. doi: 10.1093/jnci/djs527. Epub 2012 Dec 21.

47.

Cancer screening campaigns--getting past uninformative persuasion.

Woloshin S, Schwartz LM, Black WC, Kramer BS.

N Engl J Med. 2012 Nov 1;367(18):1677-9. doi: 10.1056/NEJMp1209407. No abstract available.

48.

Evaluating a new marker for risk prediction: decision analysis to the rescue.

Baker SG, Kramer BS.

Discov Med. 2012 Sep;14(76):181-8. Review.

49.

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD; PLCO Project Team.

N Engl J Med. 2012 Jun 21;366(25):2345-57. doi: 10.1056/NEJMoa1114635. Epub 2012 May 21.

50.

A population approach to precision medicine.

Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS.

Am J Prev Med. 2012 Jun;42(6):639-45. doi: 10.1016/j.amepre.2012.02.012.

Supplemental Content

Loading ...
Support Center